CFO Martin Möller to leave Biotest as planned at the end of his contract. Position of CFO to be filled in the near future.
|
EQS-Ad-hoc: Biotest AG / Key word(s): Personnel Ad hoc NOTICE
CFO Martin Möller to leave Biotest as planned at the end of his contract. Position of CFO to be filled in the near future
The Supervisory Board has already initiated the search for a suitable successor and aims to fill the position in the near future. Martin Möller will continue to support Biotest AG in an advisory capacity beyond the end of his contract.
Biotest AG www.biotest.com
Disclaimer This document contains forward-looking statements on the overall economic development and the business, earnings, financial and asset situation of Biotest AG and its subsidiaries. These statements are based on the company's current plans, estimates, forecasts and expectations and are therefore subject to risks and uncertainties that could cause actual developments to differ materially from those anticipated. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and does not assume any obligation to do so.
About Biotest Biotest (www.biotest.com) is a provider of biological therapeutics derived from human plasma. With a value-added chain that extends from preclinical and clinical development to worldwide sales, Biotest has specialized primarily in the areas of clinical immunology, hematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. Biotest has more than 2,500 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German Stock Exchange. Since May 2022, Biotest has been a part of the Grifols Group, headquartered in Barcelona, Spain (www.grifols.com).
IR contact Dr Monika Baumann (Buttkereit) PR contact Dirk Neumüller Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201
Contact: Martin MöllerChief Financial Officer Biotest AG Landsteinerstr. 5 63303 Dreieich Tel. +40 6103 801 2999 Fax: +49 6103 801 767 martin.moeller@biotest.com End of Inside Information
06-March-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
| Language: | English |
| Company: | Biotest AG |
| Landsteinerstraße 5 | |
| 63303 Dreieich | |
| Germany | |
| Phone: | 0 61 03 - 8 01-0 |
| Fax: | 0 61 03 - 8 01-767 |
| E-mail: | ir@biotest.com |
| Internet: | www.biotest.com |
| ISIN: | DE0005227235, DE0005227201 |
| WKN: | 522723, 522720 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2096222 |
| End of Announcement | EQS News Service |
|
|
2096222 06-March-2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.